Celularity transforms its intricate research, development, and manufacturing operations. This involves digitizing clinical trial data workflows and automating cell therapy production processes. Their specific approach integrates stringent quality controls and emphasizes end-to-end data traceability across complex biological product lifecycles.
This transformation creates critical dependencies on robust data governance and integrated system architectures. Breakdowns can occur in data synchronization between clinical study platforms or in manufacturing process deviations impacting product quality. This page analyzes Celularity's key digital transformation initiatives, highlighting operational challenges and potential selling opportunities.
Celularity Snapshot
Headquarters: Florham Park, NJ, United States
Number of employees: 123
Public or private: Public
Business model: B2B
Website: http://www.celularity.com
Celularity ICP and Buying Roles
Celularity sells to life sciences companies developing advanced therapeutics and requiring stringent regulatory adherence for product development and manufacturing.
Who drives buying decisions
-
Head of Clinical Operations → Manages trial execution and data collection consistency.
-
VP of Manufacturing → Oversees cell therapy production and process control enforcement.
-
Chief Quality Officer → Ensures regulatory compliance across all operational workflows.
-
Head of R&D → Directs research pipelines and data analysis integration.
Key Digital Transformation Initiatives at Celularity (At a Glance)
- Clinical Data Digitization: Standardizing patient data capture and reporting for clinical trials.
- Manufacturing Process Automation: Automating cell therapy production steps and data logging.
- Regulatory Submission System: Managing and submitting compliance documents electronically.
- R&D Platform Integration: Connecting diverse research tools for unified data analysis.
Where Celularity’s Digital Transformation Creates Sales Opportunities
| Vendor Type | Where to Sell (DT Initiative + Challenge) | Buyer / Owner | Solution Approach |
|---|---|---|---|
| Clinical Data Management Platforms | Clinical Data Digitization: incomplete patient data propagates into analysis systems before review | Head of Clinical Operations, Clinical Data Manager | Validate patient data entries against study protocols at ingestion |
| Clinical Data Digitization: regulatory audit trails lack consistent metadata across platforms | Chief Quality Officer, Head of Regulatory Affairs | Standardize audit logging and metadata capture across systems | |
| Clinical Data Digitization: external site data entries do not validate against study protocols | Clinical Data Manager, Head of Biostatistics | Enforce data validation rules for external site submissions | |
| Manufacturing Execution Systems (MES) | Manufacturing Process Automation: batch records contain manual data entry errors before submission | VP of Manufacturing, Manufacturing Operations Manager | Automate data capture directly from production equipment |
| Manufacturing Process Automation: cell culture parameters diverge from target ranges without alerts | Head of Process Development, Manufacturing Operations Manager | Route real-time alerts for critical process parameter deviations | |
| Manufacturing Process Automation: material traceability data fails to link across production stages | VP of Manufacturing, Supply Chain Director | Enforce material tracking and linking across all production steps | |
| Regulatory Information Management (RIM) Systems | Regulatory Submission System: document versions do not synchronize before agency submission | Head of Regulatory Affairs, Director of Document Control | Standardize document version control and change management |
| Regulatory Submission System: submission package compilation requires manual content verification | Head of Regulatory Affairs, Compliance Officer | Validate content against regulatory specifications during assembly | |
| Regulatory Submission System: inspection readiness documents contain outdated information internally | Chief Quality Officer, Director of Document Control | Enforce periodic review and update cycles for critical documents | |
| R&D Data Orchestration Platforms | R&D Platform Integration: genomic sequencing data fails to integrate with patient phenotype records | Head of R&D, Director of Bioinformatics | Standardize genomic data parsing and linking with patient data |
| R&D Platform Integration: experimental results do not propagate to central analytics dashboards | Head of R&D, Head of Data Science | Route experimental data into designated analysis repositories | |
| R&D Platform Integration: research data access controls fail to enforce user permissions consistently | Director of Bioinformatics, Head of IT Security | Enforce granular access policies across research data platforms |
Identify when companies like Celularity are in-market for your solutions.
Spot buying signals, find the right prospects, enrich your data, and reach out with relevant messaging at the right time.
What makes this Celularity’s digital transformation unique
Celularity’s digital transformation is highly differentiated by its focus on advanced cell therapies and the strict regulatory environment. They prioritize precise process control and data traceability due to the inherent complexity of biological products. This necessitates robust validation protocols and integrated systems across their R&D, clinical, and manufacturing workflows, creating unique challenges beyond typical enterprise transformations.
Celularity’s Digital Transformation: Operational Breakdown
DT Initiative 1: Clinical Data Digitization
What the company is doing
Celularity digitizes patient data capture and analysis for clinical trials. They implement electronic data systems for study management. This centralizes patient responses and clinical observations for regulatory review.
Who owns this
- Head of Clinical Operations
- Clinical Data Manager
- Head of Biostatistics
Where It Fails
- Patient enrollment data fails to synchronize across disparate clinical research systems.
- Adverse event reporting requires manual reconciliation between site and central databases.
- Regulatory compliance checks on clinical data entries block study progression.
Talk track
Noticed Celularity is digitizing clinical trial data workflows. Been looking at how some life science companies are standardizing data validation before analysis instead of correcting errors later, can share what’s working if useful.
DT Initiative 2: Cell Therapy Manufacturing Automation
What the company is doing
Celularity automates key steps in cell therapy production. They implement robotic systems and digital controls within manufacturing facilities. This manages precise environmental conditions and cell processing parameters.
Who owns this
- VP of Manufacturing
- Head of Process Development
- Manufacturing Operations Manager
Where It Fails
- Automated bioreactor logs do not consistently transfer to central batch record systems.
- Temperature deviations in cold chain storage block product release.
- Material identification tracking fails to update across internal logistics systems.
Talk track
Saw Celularity is automating cell therapy manufacturing processes. Been looking at how some biotech firms are enforcing real-time quality checks on production parameters instead of detecting issues post-batch, happy to share what we’re seeing.
DT Initiative 3: Regulatory Document Management
What the company is doing
Celularity establishes electronic systems for managing regulatory submissions. They digitize document authoring, review, and archival processes. This supports compliance with global health authorities and internal quality standards.
Who owns this
- Chief Quality Officer
- Head of Regulatory Affairs
- Director of Document Control
Where It Fails
- Draft regulatory documents contain uncontrolled changes before final review.
- Submission packages fail validation checks due to missing or incorrect attachments.
- Audit trails for document access do not log consistently across regional systems.
Talk track
Looks like Celularity is implementing digital regulatory document management. Been seeing teams enforce content consistency across submission modules instead of manual cross-referencing, can share what’s working if useful.
DT Initiative 4: R&D Platform Integration
What the company is doing
Celularity connects various research and development platforms. They integrate genomic data, lab results, and patient profiles. This provides a unified view for drug discovery and development decisions.
Who owns this
- Head of R&D
- Director of Bioinformatics
- Head of Data Science
Where It Fails
- Genomic sequencing data from external labs does not parse correctly into internal analysis platforms.
- Experimental results from high-throughput screening fail to associate with corresponding compound libraries.
- Research project metadata does not synchronize across project management and data repositories.
Talk track
Seems like Celularity is integrating R&D platforms for unified data access. Been looking at how some research organizations are standardizing data schemas before ingestion instead of relying on post-processing transformations, happy to share what we’re seeing.
Who Should Target Celularity Right Now
This account is relevant for:
- Clinical trial data management platforms.
- Biopharmaceutical manufacturing execution systems.
- Regulatory information management solution providers.
- R&D data integration and governance platforms.
- Quality management system (QMS) software vendors.
- Supply chain traceability solutions for highly regulated industries.
Not a fit for:
- Generic marketing automation platforms.
- Standard HR payroll systems.
- Basic e-commerce solutions.
- Generalist IT infrastructure providers.
When Celularity Is Worth Prioritizing
Prioritize if:
- You sell systems for consistent patient data validation in clinical trials.
- You sell platforms for real-time monitoring of bioprocess manufacturing parameters.
- You sell solutions for automated regulatory document compilation and validation.
- You sell tools for standardizing genomic data ingestion into research platforms.
- You sell software enforcing material traceability across complex production workflows.
Deprioritize if:
- Your solution does not address any of the breakdowns above.
- Your product lacks compliance features for highly regulated industries.
- Your offering focuses on non-core business functions like marketing or general sales.
Who Can Sell to Celularity Right Now
Clinical Data Management Platforms
Medidata Solutions - This company provides cloud-based solutions for clinical development, including electronic data capture and clinical trial management.
Why they are relevant: Incomplete patient data propagates into analysis systems during clinical trials. Medidata can centralize data collection, enforce data standards, and validate entries to ensure data integrity for regulatory submissions and analyses.
Veeva Systems - This company offers cloud-based software for the life sciences industry, focusing on R&D, clinical, quality, and commercial operations.
Why they are relevant: Regulatory audit trails lack consistent metadata across clinical data platforms. Veeva's clinical and quality suites can provide unified data governance and audit capabilities across study management and compliance documentation.
Oracle Health Sciences - This company provides a suite of applications for clinical research, pharmacovigilance, and healthcare management.
Why they are relevant: External site data entries do not validate against study protocols before ingestion. Oracle's clinical data management tools can implement real-time validation rules and checks to ensure protocol adherence and data quality from all trial sites.
Manufacturing Execution Systems (MES)
Werum IT Solutions - This company specializes in manufacturing execution systems specifically for the pharmaceutical and biotech industries.
Why they are relevant: Batch records contain manual data entry errors during cell therapy production. Werum's MES can automate data capture directly from equipment, enforce procedural steps, and eliminate manual recording errors in batch documentation.
Siemens Opcenter Execution Pharma - This company offers an MES solution designed for pharmaceutical and biotech manufacturing.
Why they are relevant: Cell culture parameters diverge from target ranges without immediate alerts during production. Siemens Opcenter can monitor critical process parameters in real-time, trigger alerts on deviations, and enforce corrective actions within automated workflows.
Rockwell Automation (Pharma MES) - This company provides control systems and MES solutions for industrial automation, including biotech manufacturing.
Why they are relevant: Material traceability data fails to link across production stages within the manufacturing process. Rockwell's MES capabilities can provide end-to-end material tracking, ensuring complete chain of custody for regulatory compliance.
Regulatory Information Management (RIM) Systems
IQVIA RIM - This company offers comprehensive regulatory information management solutions for life sciences.
Why they are relevant: Draft regulatory documents contain uncontrolled changes before final review and submission. IQVIA's RIM platform can enforce document version control, track all modifications, and manage approval workflows to prevent unauthorized alterations.
Extedo - This company specializes in solutions for electronic regulatory affairs, focusing on e-submission and drug safety.
Why they are relevant: Submission package compilation requires manual content verification for accuracy. Extedo's tools can automate the assembly of electronic submissions, validate content against regulatory specifications, and ensure completeness before dispatch.
MasterControl - This company provides quality management and document control software for regulated industries.
Why they are relevant: Audit trails for document access do not log consistently across regional systems. MasterControl's QMS can standardize document control processes, ensure complete audit trails, and manage compliance across diverse regulatory requirements.
R&D Data Integration & Governance Platforms
Benchling - This company offers a cloud-based platform for R&D, combining ELN, LIMS, and molecular biology tools.
Why they are relevant: Genomic sequencing data from external labs does not parse correctly into internal analysis platforms. Benchling's platform can standardize data ingestion, ensure proper formatting, and integrate diverse R&D data types for seamless analysis.
Dotmatics - This company provides a scientific R&D platform for chemistry and biology.
Why they are relevant: Experimental results from high-throughput screening fail to associate with corresponding compound libraries. Dotmatics can link experimental data directly to compound structures and project metadata, ensuring accurate correlation and traceability.
Tempus AI (Data Platform) - This company uses AI and proprietary data to accelerate precision medicine, with a strong data platform component.
Why they are relevant: Research project metadata does not synchronize across project management and data repositories. Tempus' data platform capabilities can provide unified metadata management, ensuring consistent data context across R&D initiatives.
Final Take
Celularity scales complex R&D and manufacturing for advanced cell therapies. Breakdowns appear in clinical data integrity, manufacturing process control, regulatory document synchronization, and R&D data integration. This account is a strong fit for vendors addressing these critical operational failures within highly regulated biopharmaceutical environments.
Identify buying signals from digital transformation at your target companies and find those already in-market.
Find the right contacts and use tailored messages to reach out with context.